Kyverna Therapeutics Inc. – Filings and Transcripts

NASDAQ: KYTX
Share price (9/21/26): $7.12
Market cap (9/21/26): $440 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Registration of securities for employees

Shelf registration

Prospectus supplement for primary offering

Free writing prospectus

Ownership Filter

Bain Capital Life Sciences Opportunities III, LP

Seidenberg Beth C

News Filter

Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics and ElevateBio Enter Into Commercial Manufacturing and Supply Agreement for Miv-Cel

Material Definitive Agreement, Financial Statements or Exhibits

Shareholder Vote Results, Financial Statements or Exhibits

Names Greg Martini as Chief Financial Officer

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness